From: Immunotherapy in head and neck cancer: aiming at EXTREME precision
Trial, ClinicalTrials.gov identifier | Phase | Estimated enrolment | Immunotherapeutic approach | Regimen (treatment arms A, B, C) | Primary completion date |
---|---|---|---|---|---|
NCT02105636 (CheckMate-141) | III | 361d | Anti-PD-1 | A: Nivolumab B: SoC | 11/2015 |
NCT02319044 (CONDOR)b | IIR | 240 | Anti-PD-L1 Anti-CTLA-4 | A: Durvalumab B: Tremelimumab C: Durvalumab + tremelimumab | 9/2016 |
NCT02252042 (KEYNOTE-040) | III | 466 | Anti-PD-1 | A: Pembrolizumab B: SoC | 5/2017 |
NCT02369874 (EAGLE) | III | 720 | Anti-PD-L1 Anti-CTLA-4 | A: Durvalumab B: Durvalumab + tremelimumab C: SoC | 2/2018 |
NCT02611960c (KEYNOTE-122) | IIR | 160 | Anti-PD-1 | A: Pembrolizumab B: SoC | 1/2019 |